Pulmonx Corporation (LUNG)
Stock Price:
$42.24 USD
-0.82 (-1.90%)
Updated Oct 23, 2020 4:00 PM EDT - Market closed
Key Info
| Market Cap |
1.43B |
| Revenue (ttm) |
31.74M |
| Net Income (ttm) |
-28.08M |
| Shares Out |
32.47M |
| EPS (ttm) |
-0.86 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
Oct 23, 2020 |
| Last Price |
$42.24 |
| Previous Close |
$43.06 |
| Change ($) |
-0.82 |
| Change (%) |
-1.90% |
| Day's Open |
42.89 |
| Day's Range |
40.47 - 43.92 |
| Day's Volume |
332,780 |
| 52-Week Range |
37.64 - 52.00 |
More Stats
| Market Cap |
1.43B |
| Enterprise Value |
1.44B |
| Earnings Date (est) |
n/a |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
32.47M |
| Float |
7.13M |
| EPS (basic) |
n/a |
| EPS (diluted) |
-0.86 |
| FCF / Share |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
n/a |
| Short Ratio |
n/a |
| Short % of Float |
n/a |
| Beta |
n/a |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
45.15 |
| PB Ratio |
42.80 |
| Revenue |
31.74M |
| Operating Income |
n/a |
| Net Income |
-28.08M |
| Free Cash Flow |
n/a |
| Net Cash |
-10.35M |
| Net Cash / Share |
-0.31 |
| Gross Margin |
70.61% |
| Operating Margin |
n/a |
| Profit Margin |
-88.46% |
| FCF Margin |
n/a |
| ROA |
n/a |
| ROE |
n/a |
| ROIC |
n/a |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Summary
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 |
|---|
| Revenue | 32.60 | 20.00 |
| Revenue Growth | 62.94% | - |
| Gross Profit | 22.41 | 12.29 |
| Operating Income | -17.84 | -15.05 |
| Net Income | -20.70 | -18.48 |
| Shares Outstanding | 1.78 | 1.67 |
| Earnings Per Share | -11.66 | -11.03 |
| Operating Cash Flow | -20.77 | -18.39 |
| Capital Expenditures | -0.72 | -0.30 |
| Free Cash Flow | -21.49 | -18.69 |
| Cash & Equivalents | 28.35 | 4.12 |
| Total Debt | 21.81 | 33.61 |
| Net Cash / Debt | 6.53 | -29.48 |
| Assets | 53.53 | 15.01 |
| Liabilities | 35.57 | 41.80 |
| Book Value | -187 | -167 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Pulmonx Corporation |
| Country |
United States |
| Employees |
202 |
| CEO |
Glendon E. French |
Stock Information
| Ticker Symbol |
LUNG |
| Stock Exchange |
NASDAQ |
| Sector |
Health Technology |
| Industry |
Medical Specialties |
| Unique Identifier |
NASDAQ: LUNG |
| IPO Date |
October 1, 2020 |
Description
Pulmonx Corporation, a medical technology company, designs, develops, manufactures, and markets minimally invasive medical devices for the diagnosis and treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of bronchoscopic in adult patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in Europe, the Middle East, Africa, the Asia-Pacific, the United States, and internationally. Pulmonx Corporation was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.